Mild-to-moderate Ulcerative Colitis induction therapy: budesonide (CORE studies) Once-daily Budesonide MMX® Extended-Release Tablets Induce Remission in Patients With Mild to Moderate Ulcerative Colitis: Results From the CORE I Study William J Sandborn, Simon Travis, Luigi Moro , Richard Jones, Theres Gautille, Robert Bagin , Michael Huang, Phil Yeung, E David Ballard Background & aims: Budesonide is a corticosteroid with minimal systemic corticosteroid activity ..
Tag : induction
Related articles:*Acute severe colitis*Mild-to-Moderate Ulcerative Colitis*Probiotics in Ulcerative Colitis*Methotrexate in Ulcerative Colitis*Infliximab Ulcerative Colitis*Infliximab with Azathiopurine (Ulcerative Colitis)*Acute severe colitis: Accelerated induction Infliximab*Adalimumab in Ulcerative Colitis (ULTRA studies)*Golimumab in Ulcerative Colitis*Vedolizumab vs Adalimumab Ulcerative Colitis*Vedolizumab Ulcerative Colitis*Ustekinumab (Ulcerative colitis)*Acute severe colitis: Infliximab vs ciclosporin (CONTRUCT) Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis (2017) ..
Efficacy of anti-TNF maintenance therapy in Fistulas in Crohn’s Disease patients. In a meta-analysis it was found that TNF antagonists are effective for induction and maintenance of perianal fistula response and remission. Efficacy of anti-TNF as induction therapy in fistulas Efficacy of anti-TNF as maintenance therapy in fistulas References: Lee, M. J., Parker, C. E., ..
Vedolizumab in Crohn Related articles (Crohn):*Azathioprine Crohn*Methotrexate in Crohn*Infliximab in Crohn (ACCENT I)*Infliximab with Azathiopurine (Crohn)*Infliximab with Methotrexate (Crohn)*Infliximab switch to Adalimumab in Crohn (GAIN/ADHERE trial)*Adalimumab (CLASSIC & CHARM trial – Crohn)*Adalimumab with immunomodulator (Crohn)*Ustekinumab (UNITI trial – Crohn – 2016) BackgroundThe efficacy of vedolizumab, an α4β7 integrin antibody, in Crohn’s disease is unknown. MethodsIn ..
Recent Comments